Clinical Feasibility Study of Prototype 1.5T & 3T Endorectal Coils

Completed

Conditions: prostate cancer
10038597

Registration Number: NL-OMON34331

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 8

Inclusion Criteria

• Newly diagnosed and biopsy proven prostate cancer
• No previous treatment for prostate cancer
• Signed informed consent by patient
• 18 years of age or more
• Signed screening form (to search for metal device/foreign bodies/claustrophobia)
• No contraindications for and are eligible to have a MR scan of their prostate utilizing an endorectal coil

Exclusion Criteria

• Impossibility to obtain a valid informed consent
• Patients unable to undergo MR imaging, including those with contra-indications
• Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Investigational 1.5T and 3.0T Siemens eCoils, tuning devices and the<br /><br>appropriate configuration files to enable use of the coil will be provided for<br /><br>the purpose of this study. Patients will be positioned on the scanner table and<br /><br>the eCoil inserted by an experienced radiologist. All coils will be filled<br /><br>with perfluorocarbon. Patients will then be scanned utilizing the imaging<br /><br>protocol, (pulse sequences noted above) as are normally employed by the<br /><br>radiology department of the RUNMC when performing endorectal prostate MR<br /><br>studies on their patients. Images obtained with the investigational four<br /><br>channel output eCoil in conjunction with or without a surface coil and images<br /><br>obtained using commercial 1.5T endorectal probes with any fluids other than air<br /><br>are NOT to be used for diagnostic purposes. </p><br>

Secondary Outcome Measures